Bangalore, Nov 13, 2009: SIRO Clinpharm, a global CRO with a base in India,US, Europe and Israel, has entered into an alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France.

Mediscis is an established expert in GCP compliant early phase drug development services including clinical trials and bioanalytics; SIRO offers expertise across all study phases for the pharmaceutical and biotech industry.

 

“This will be an important collaboration for both the parties as they stand to gain access to each others’ core competencies. This alliance will allow us to provide additional services to our global clients to support their clinical development plans,” said Mr Scott Spector, President, Strategic Operations, Europe.

 

“Following the acquisition of Omega Mediation Clinical Research Services, SIRO was able to establish a footprint in the European clinical research market. We envision becoming a leading drug development solutions provider by delivering compelling value propositions to the global healthcare industry. From this alliance, we are glad that we can offer a larger bouquet of services to our global clientele and move closer to our vision,” said Dr Chetan Tamhankar, Chief Operating Officer of SIRO Clinpharm.